—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why. A new study published in JAMA Oncology from ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

CLEVELAND – Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ...

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally ...